Key result
Enteric-coated low-dose aspirin (81 mg daily) for 7 days achieved 97.4% mean inhibition of serum thromboxane B2 compared to a 7.8% increase with placebo.
Why the study?
Does enteric-coated low-dose aspirin reduce serum thromboxane B2 and platelet aggregation in healthy subjects?
RCT (n=24)
double-blind
randomized
Does enteric-coated low-dose aspirin reduce serum thromboxane B2 and platelet aggregation in healthy subjects?
Absolute Event Rate: 97.4% vs -7.8%
Enteric-coated low-dose aspirin effectively inhibits serum thromboxane B2 and platelet aggregation, demonstrating that its anti-platelet efficacy is not adversely affected by the enteric coating.
No takes yet. Share an insight, caveat, or question.
Supports enteric-coated aspirin use despite coating concerns; confirms reliable antiplatelet efficacy in randomized data.
Hecken et al. (2002) conducted an RCT in healthy subjects (n=24). enteric-coated aspirin vs. placebo was evaluated on mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2. Enteric-coated low-dose aspirin (81 mg daily) for 7 days achieved 97.4% mean inhibition of serum thromboxane B2 compared to a 7.8% increase with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: